Close menu




July 14th, 2026 | 07:00 CEST

Bayer and Novo Nordisk Celebrate a Comeback! Is BioNxt Solutions Next?

  • Biotechnology
  • Biotech
  • Pharma
  • Innovations
Photo credits: Novo Nordisk

With its GLP-1 therapy in tablet form, Novo Nordisk has returned to success on the stock market. Since April, the Danish pharmaceutical company's stock has risen by nearly 50% to around EUR 43. New research results are now being presented. Bayer has also recently celebrated a comeback on the stock market. Following the landmark glyphosate ruling by the US Supreme Court, hopes are growing that the company will be able to focus more strongly on its core business again in the future. To that end, the Leverkusen-based company has secured EUR 3 billion. BioNxt Solutions could be poised for a comeback. The biotech company's stock has nearly halved in value this year. Yet the news flow is positive and points to rising prices.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: BAYER AG NA O.N. | DE000BAY0017 , NOVO NORDISK A/S | DK0062498333 , Bionxt Solutions Inc. | CA0909741062 | CSE:BNXT , OTCQB: BNXTF

Table of contents:


    BioNxt Shares Poised for a Comeback?

    BioNxt Solutions focuses on developing innovative dosage forms for already-approved blockbuster active ingredients. Using its sublingual, thin-film dissolvable technology, the Canadian-German biotech company aims to bring new drug variants to market within a few years. Compared to developing entirely new active ingredients, this reduces development costs and research risks.
    The stock has nearly halved in value this year. This could present a buying opportunity. The company is well on its way to commercializing the drug candidate BNT23001. BioNxt is currently preparing a human bioavailability study to compare BNT23001 with Mavenclad, both at a dosage of 10 mg. BNT23001 is a patented, sublingual cladribine formulation in the form of an orally dissolvable film for the treatment of multiple sclerosis. The product is intended to offer an alternative to cladribine tablets, such as Mavenclad and could be particularly beneficial for patients who have difficulty swallowing.

    At the same time, BioNxt is preparing for commercialization. To this end, the company has hired a specialized consultant for business development and licensing. Together, they will explore potential licensing agreements, regional marketing partnerships, joint development models, and other strategic collaborations. Another factor driving this effort is the high market potential. Mavenclad generated global sales of approximately EUR 1.2 billion in 2025.

    In addition, BioNxt Solutions is continuing to advance the development of a sublingual, orally soluble semaglutide film. The goal is to provide a needle-free and patient-friendly alternative to injectable GLP-1 therapies for type 2 diabetes, obesity, and weight management. The thin films are designed to dissolve under the tongue and, upon absorption through the oral mucosa, bypass the gastrointestinal tract and hepatic first-pass metabolism. The company is thus targeting a rapidly growing market worth billions.

    Novo Nordisk Reports Research Success

    With its GLP-1 therapy in tablet form, Novo Nordisk has returned to success on the stock market. Since April, the Danish pharmaceutical company's stock has risen by nearly 50% to around EUR 43. But Novo Nordisk is not relying solely on its blockbuster drugs Wegovy and Ozempic, or on acquisitions. The company continues to invest heavily in its own research and is now reporting promising study data from an entirely different therapeutic area.

    At the ISTH 2026 conference, Novo Nordisk presented positive interim results from the Phase 3 long-term FRONTIER4 study on denecimig, also known as Mim8. The drug, which has not yet been approved, is administered as a preventive subcutaneous injection for hereditary bleeding disorders. The study included 426 children, adolescents, and adults with and without so-called inhibitors—antibodies that can render conventional factor preparations ineffective. Denecimig demonstrated overall stable efficacy and a favourable safety profile when administered weekly, biweekly, and monthly.

    The average annualized bleeding rate, that is, the calculated number of treatment-requiring bleeds per year, was 0.75 for adults and adolescents and 0.37 for children. Approximately 71% of adults and adolescents and 89% of children had no treatment-requiring bleeds during treatment.

    In addition, Novo Nordisk presented data on concizumab from the Phase 3 Explorer10 study involving 24 children under the age of 12 with hemophilia A or B and inhibitors. Prophylactic treatment reduced the annualized bleeding rate by 82% compared with on-demand therapy alone. Most side effects were mild, although 29% of participants experienced serious adverse events. Denecimig has been undergoing the approval process with the US Food and Drug Administration (FDA) since September 2025. Both active ingredients are intended to improve blood clotting, but they act on different parts of the coagulation system.

    Bayer Raises Fresh Capital

    Following the US Supreme Court's landmark glyphosate ruling, there is a sense of optimism at Bayer. The decision strengthens the company's position in ongoing legal disputes and could significantly mitigate the liability risks that have weighed on the company for years. Since early June, the stock has climbed from EUR 34 to 50. This is the highest price level since September 2023. Hopes are growing that the company will once again be able to focus more strongly on its core business, its pharmaceutical pipeline, and long-term growth.

    To continue accelerating its operations, Bayer has secured EUR 3 billion in equity through an agreement with the asset manager Apollo. In return, Apollo will receive a minority stake in a new company into which Bayer is spinning off its business with reversible long-acting contraceptives. Bayer retains both the majority stake and full operational control. The business will remain part of the Pharmaceuticals division and will continue to be fully consolidated in the Group's financial statements. With this transaction, Bayer aims to strengthen its capital structure and create additional financial flexibility to cushion higher liquidity pressures resulting from maturing bonds and legal disputes. The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals.


    Bayer and Novo Nordisk demonstrate how quickly stocks can turn and make a comeback. This could also be on the horizon for BioNxt Solutions. The news flow from the biotech company is positive. Bayer and Novo Nordisk have performed well in recent months. A breather for both stocks would come as no surprise.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Carsten Mainitz on November 10th, 2026 | 05:45 CET

    Exciting pharma duel: Who will take off now - BioNxt Solutions, Bayer or Novo Nordisk?

    • Pharma
    • Biotech
    • Innovations
    • Diabetes

    New active ingredients, expanded indications and more user-friendly dosage forms are driving momentum in the global pharmaceutical market. BioNxt Solutions is focusing on novel oral dissolvable films and working towards regulatory and clinical breakthroughs. Industry heavyweights Bayer and Novo Nordisk have recently reported solid quarterly results. Bayer has already overcome several challenges and raised its outlook. At the same time, Novo Nordisk is impressively demonstrating how innovative forms of administration in obesity treatment can achieve soaring commercial success. Where do the most attractive opportunities for investors lie following the latest developments?

    Read

    Commented by Nico Popp on November 9th, 2026 | 23:05 CET

    Billion-dollar opportunity in cardiac therapy: Cardiol Therapeutics, Kiniksa and Novo Nordisk

    • Pericarditis
    • Cardiovascular diseases
    • Biotech

    Created and Published on Behalf of Cardiol Therapeutics

    The treatment of inflammatory heart diseases is becoming one of the most lucrative segments of the pharmaceutical industry. The only drug approved to date for recurrent pericarditis is expected to exceed USD 1 billion in revenue this year. While established industry heavyweights generate enormous revenues from injectable biologics, emerging biotechnology companies are preparing the next stage of development. The focus is on the search for oral therapies intended to open up access to treatment for a much broader patient population.

    Read

    Commented by Lars Winter on November 6th, 2026 | 05:35 CET

    Gold potential, pharma comeback and AI boom: Lahontan Gold, Bayer and AMD in Focus

    • Lahontan Gold
    • Bayer
    • AMD
    • Gold stocks
    • Santa Fe
    • West Santa Fe
    • Nevada
    • Gold exploration
    • Silver
    • Economic viability study
    • Drilling results
    • Pharma
    • Nubeqa
    • Kerendia
    • Asundexian
    • Turnaround
    • Semiconductors
    • artificial intelligence
    • Data centres

    A gold project with enormous return potential, a pharmaceutical group with fresh tailwinds and a chip designer on course for records: Lahontan Gold, Bayer and AMD are currently delivering exciting news. The leverage is particularly strong at the Canadian gold developer, whose Santa Fe project promises enormous growth potential according to the PEA. Bayer, meanwhile, recently raised its earnings targets, while AMD is benefiting from the expansion of data centres. We examine where the opportunities now lie and where investors need to look more closely - three interesting stocks under review.

    Read